Christine J. Weegink

Author

Amsterdam UMC Location University of Amsterdam

Also Known As

C J Weegink, C Weegink, C. J. Weegink, C. Weegink, C.J. Weegink, Christine J Weegink, Christine J. Weegink, Christine Weegink, Weegink, C. J., Weegink, Christine J.

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location University of Amsterdam University of Amsterdam GGD Amsterdam Erasmus MC Vertex Pharmaceuticals (United States)

About

Christine J. Weegink is an author at Amsterdam UMC Location University of Amsterdam specializing in hepatitis, viral hepatitis, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	2K
2	Hepatology	11	11	1.7K
3	Epidemiology	3	3	87
4	Public Health	2	2	55
5	Health Informatics	1	1	27

Christine J. Weegink

Publications

Citations

H-Index

Page 1

	Year	Citations
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir Christoph Sarrazin, Tara L. Kieffer, Doug J. Bartels, Gastroenterology HepatologyHepatitis CPatients TreatedViral HepatitisPhenotypic Changes	2007	611
Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study Hendrik W. Reesink, Stefan Zeuzem, Christine J. Weegink, Gastroenterology Viral PersistenceHepatologyHepatitis CViral HepatitisRapid Decline	2006	394
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study Geoffrey Dusheiko, Janice Main, H. C. Thomas, Journal of Hepatology HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	1996	352
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C Nicole Forestier, Hendrik W. Reesink, Christine J. Weegink, Hepatology	2007	253
Sexual transmission of hepatitis C virus Dorine Bresters, H. W. Reesink, C.L. van der Poel, The Lancet Sexual HealthViral PersistenceHepatitis CHepatitis C VirusViral Hepatitis	1993	231
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients H. W. Reesink, Gregory Fanning, Khalid Abou Farha, Gastroenterology Viral PersistenceHepatologyHepatitis CViral HepatitisHepatitis C Patients	2009	155
Hepatitis C testing and treatment among active drug users in Amsterdam Catharina E. A. Lindenburg, Femke A.E. Lambers, Anouk T. Urbanus, European Journal of Gastroenterology & Hepatology	2010	84
Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and Adefovir R. Bart Takkenberg, Louis Jansen, A. de Niet, Antiviral Therapy	2013	77
Performance of the New Bayer VERSANT HCV RNA 3.0 Assay for Quantitation of Hepatitis C Virus RNA in Plasma and Serum: Conversion to International Units and Comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, Assay Marcel Beld, Roel Sentjens, Sjoerd Rebers, Journal of Clinical Microbiology	2002	69
Chronic hepatitis E after solid organ transplantation. A. de Niet, Hans L. Zaaijer, Ineke ten Berge, PubMed	2012	60

Page 1